The DOI matches its Crossref record; 30 of the 30 references it cites were found in a registry or an index.
Immunotherapy for Guillain-Barre syndrome: a systematic review
Open accessAbstract
Guillain-Barré syndrome (GBS) is an acute inflammatory disorder of the peripheral nervous system thought to be due to autoimmunity for which immunotherapy is usually prescribed. To provide the best evidence on which to base clinical practice, we systematically reviewed the results of randomized trials of immunotherapy for GBS. We searched the Cochrane Library, MEDLINE and EMBASE in July 2006 and used the methods of the Cochrane Neuromuscular Disease Group to extract and synthesize data. Almost all trials used a 7-point disability grade scale. In four trials with altogether 585 severely affected adult participants, those treated with plasma exchange (PE) improved significantly more on this scale 4 weeks after randomization than those who did not, weighted mean difference (WMD) -0.89 (95% confidence interval (CI) -1.14 to -0.63). In five trials with altogether 582 participants, the improvement on the disability grade scale with intravenous immunoglobulin (IVIg) was very similar to that with PE, WMD -0.02 (95% CI -0.25 to 0.20). There was also no significant difference between IVIg and PE for any of the other outcome measures. In one trial with 148 participants, following PE with IVIg did not produce significant extra benefit. Limited evidence from three open trials in children suggested that IVIg hastens recovery compared with supportive care alone. Corticosteroids were compared with placebo or supportive treatment in six trials with altogether 587 participants. There was significant heterogeneity in the analysis of these trials which could be accounted for by analysing separately four small trials of oral corticosteroids with altogether 120 participants, in which there was significantly less improvement after 4 weeks with corticosteroids than without, WMD -0.82 (95% CI -0.17 to -1.47), and two large trials of intravenous methylprednisolone with altogether 467 participants, in which there was no significant difference between corticosteroids and placebo WMD -0.17 (95% CI 0.06 to -0.39). None of the treatments significantly reduced mortality. Since approximately 20% of patients die or have persistent disability despite immunotherapy, more research is needed to identify better treatment regimens and new therapeutic strategies.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Hughes, R. A., & Cornblath, D. R. (2005) · The Lancet · doi:10.1016/s0140-6736(05)67665-9 · Cited by 1,676
Self-citationvan der Meché, F. G. A., Schmitz, P. I. M., & the Dutch Guillain–Barré Study Group* (1992) · New England Journal of Medicine · doi:10.1056/nejm199204233261705 · Cited by 1,143
CONTROLLED TRIAL OF PREDNISOLONE IN ACUTE POLYNEUROPATHY
Hughes, R. A. C., Newsom-Davis, J. M., Perkin, G. D., & Pierce, J. M. (1978) · The Lancet · doi:10.1016/s0140-6736(78)92644-2 · Cited by 1,123
Self-citationKleyweg, R. P., Van Der Meché, F. G. A., & Schmitz, P. I. M. (1991) · Muscle & Nerve · doi:10.1002/mus.880141111 · Cited by 926
Intravenous immunoglobulin for Guillain-Barré syndrome
Hughes, R. A., Swan, A. V., & van Doorn, P. A. (2014) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd002063.pub6 · Cited by 721
Self-citationPeripheral neuropathies and anti-glycolipid antibodies
Willison, H. J. (2002) · Brain · doi:10.1093/brain/awf272 · Cited by 710
Desforges, J. F., & Ropper, A. H. (1992) · New England Journal of Medicine · doi:10.1056/nejm199204233261706 · Cited by 696
(1997) · Transfusion Medicine Reviews · doi:10.1016/s0887-7963(97)80059-4 · Cited by 610
Yuki, N., Susuki, K., Koga, M., Nishimoto, Y., Odaka, M., Hirata, K., Taguchi, K., Miyatake, T., Furukawa, K., Kobata, T., et al. (2004) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0402391101 · Cited by 498
Griffin, J. W., Li, C. Y., Ho, T. W., Xue, P., Macko, C., Gao, C. Y., Yang, C., Tian, M., Mishu, B., Cornblath, D. R., et al. (1995) · Brain · doi:10.1093/brain/118.3.577 · Cited by 366
Cited by
Willison, H. J., Jacobs, B. C., & van Doorn, P. A. (2016) · The Lancet · doi:10.1016/s0140-6736(16)00339-1 · Cited by 1,609
Self-citationYuki, N., & Hartung, H.-P. (2012) · New England Journal of Medicine · doi:10.1056/nejmra1114525 · Cited by 1,260
Guillain–Barré syndrome: pathogenesis, diagnosis, treatment and prognosis
van den Berg, B., Walgaard, C., Drenthen, J., Fokke, C., Jacobs, B. C., & van Doorn, P. A. (2014) · Nature Reviews Neurology · doi:10.1038/nrneurol.2014.121 · Cited by 1,101
Self-citationBrahmer, J. R., Abu-Sbeih, H., Ascierto, P. A., Brufsky, J., Cappelli, L. C., Cortazar, F. B., Gerber, D. E., Hamad, L., Hansen, E., Johnson, D. B., et al. (2021) · Journal for ImmunoTherapy of Cancer · doi:10.1136/jitc-2021-002435 · Cited by 917
Diagnosis and management of Guillain–Barré syndrome in ten steps
Leonhard, S. E., Mandarakas, M. R., Gondim, F. A. A., Bateman, K., Ferreira, M. L. B., Cornblath, D. R., van Doorn, P. A., Dourado, M. E., Hughes, R. A. C., Islam, B., et al. (2019) · Nature Reviews Neurology · doi:10.1038/s41582-019-0250-9 · Cited by 910
Self-citationClinical features, pathogenesis, and treatment of Guillain-Barré syndrome
van Doorn, P. A., Ruts, L., & Jacobs, B. C. (2008) · The Lancet Neurology · doi:10.1016/s1474-4422(08)70215-1 · Cited by 828
Self-citationIntravenous immunoglobulin for Guillain-Barré syndrome
Hughes, R. A., Swan, A. V., & van Doorn, P. A. (2014) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd002063.pub6 · Cited by 721
Self-citationUpdate on the use of immunoglobulin in human disease: A review of evidence
Perez, E. E., Orange, J. S., Bonilla, F., Chinen, J., Chinn, I. K., Dorsey, M., El-Gamal, Y., Harville, T. O., Hossny, E., Mazer, B., et al. (2017) · Journal of Allergy and Clinical Immunology · doi:10.1016/j.jaci.2016.09.023 · Cited by 666
Sejvar, J. J., Kohl, K. S., Gidudu, J., Amato, A., Bakshi, N., Baxter, R., Burwen, D. R., Cornblath, D. R., Cleerbout, J., Edwards, K. M., et al. (2011) · Vaccine · doi:10.1016/j.vaccine.2010.06.003 · Cited by 652
Self-citationBickerstaff brainstem encephalitis and Fisher syndrome: anti-GQ1b antibody syndrome
Shahrizaila, N., & Yuki, N. (2013) · Journal of Neurology, Neurosurgery & Psychiatry · doi:10.1136/jnnp-2012-302824 · Cited by 317
NCCN Task Force Report: Management of Neuropathy in Cancer
Stubblefield, M. D., Burstein, H. J., Burton, A. W., Custodio, C. M., Deng, G. E., Ho, M., Junck, L., Morris, G. S., Paice, J. A., Tummala, S., et al. (2009) · Journal of the National Comprehensive Cancer Network · doi:10.6004/jnccn.2009.0078 · Cited by 257
Guillain-Barré syndrome and anti-ganglioside antibodies: A clinician-scientist’s journey
YUKI, N. (2012) · Proceedings of the Japan Academy Series B · doi:10.2183/pjab.88.299 · Cited by 109
Metadata
- Authors
- Hughes, R. A. C., Swan, A. V., Raphael, J.-C., Annane, D., van Koningsveld, R., & van Doorn, P. A.
- Venue
- Brain
- Publisher
- Oxford University Press (OUP)
- Published
- 2007-09-01
- Volume
- 130
- Issue
- 9
- Pages
- 2245-2257
- ISSN
- 0006-8950 (ISSN-L)
- 1460-2156
- OpenAlex
- W2127884861
- Cited by
- 463
- References
- 30
- FWCI
- 2.81
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.